Trump Administration Blocks FDA Fast-Track for Psychedelic Treatment
- FDA Plan Rejected: The Trump administration officials declined to approve the FDA's plan to fast-track Compass Pathways' (CMPS) psychedelic treatment for severe depression, indicating possible internal disagreements that could affect the speed and direction of future drug approvals.
- Drug Not Approved: Although Compass's psychedelic treatment was on the FDA's list for expedited review, it was vetoed when presented to the Health and Human Services Department and the White House, highlighting inconsistencies in policy execution that may lead to decreased market confidence.
- Market Reaction: Compass Pathways shares fell 1.1% in premarket trading following the news, reflecting investor concerns about the company's future drug development prospects, which could impact its financing and R&D capabilities.
- Clinical Trial Plans Stalled: This veto may delay Compass's clinical trial plans for treatment-resistant depression and PTSD, affecting its market competitiveness and commercialization readiness.
Trade with 70% Backtested Accuracy
Analyst Views on CMPS
About CMPS
About the author
Trump Administration Blocks FDA Fast-Track for Psychedelic Treatment
- FDA Plan Rejected: The Trump administration officials declined to approve the FDA's plan to fast-track Compass Pathways' (CMPS) psychedelic treatment for severe depression, indicating possible internal disagreements that could affect the speed and direction of future drug approvals.
- Drug Not Approved: Although Compass's psychedelic treatment was on the FDA's list for expedited review, it was vetoed when presented to the Health and Human Services Department and the White House, highlighting inconsistencies in policy execution that may lead to decreased market confidence.
- Market Reaction: Compass Pathways shares fell 1.1% in premarket trading following the news, reflecting investor concerns about the company's future drug development prospects, which could impact its financing and R&D capabilities.
- Clinical Trial Plans Stalled: This veto may delay Compass's clinical trial plans for treatment-resistant depression and PTSD, affecting its market competitiveness and commercialization readiness.
Compass Receives FDA Approval for COMP360 PTSD Clinical Trial
- Clinical Trial Launch: The FDA's acceptance of the IND application for COMP360 enables Compass to initiate a Phase 2b/3 clinical trial for PTSD, which is expected to significantly advance the development of new therapies and meet the urgent market demand for effective treatments.
- Commercialization Readiness: Compass is preparing for the market launch of COMP360 for treatment-resistant depression (TRD) by the end of 2026, aiming to address the current gap in the market with only two FDA-approved medications available for approximately 4 million TRD patients.
- Strategic Collaboration Expansion: Compass has partnered with Radial, a national network of mental health treatment clinics, to enhance the integration of COMP360 into various healthcare settings, thereby increasing its market competitiveness and improving patient access to treatment.
- Increased Financial Flexibility: Compass amended its loan agreement with Hercules Capital to increase the loan size to $150 million, providing greater financial flexibility to support future clinical trials and commercialization efforts, ensuring the company maintains sufficient cash flow through 2027.
Compass Pathways Partners with Radial Health to Advance COMP360 Treatment Models
- Strategic Collaboration Expansion: Compass Pathways has entered its seventh strategic collaboration with Radial Health to optimize scalable delivery models for the COMP360 psilocybin treatment, which could significantly enhance patient treatment options if FDA approved.
- National Network Development: Radial Health operates across five states in the U.S., aiming to build a national network of interventional psychiatry clinics, and through collaboration with Compass, will facilitate the integration of innovative treatment options to improve patient experiences.
- Innovative Treatment Potential: The COMP360 psilocybin treatment is viewed as a potential paradigm shift in mental health treatment, and both parties will explore its application within Radial's delivery model, which could provide more effective treatment options for patients if successful.
- Diverse Collaboration Model: Compass has established partnerships with various mental health organizations, gathering valuable insights on how the COMP360 treatment can be integrated into different healthcare settings, thereby enhancing its market acceptance.
Post-Market Surge: Stoke Therapeutics, Alpha Tau Medical, and Compass Pathways Top Biotech Gainers
Biotech Stock Movements: Biotech stocks experienced significant fluctuations in after-hours trading, with several companies rebounding after losses during regular trading hours, driven by clinical data, FDA designations, and financing news.
Stoke Therapeutics Surge: Stoke Therapeutics saw its stock rise to $33.95 (+11.42%) after presenting positive data on zorevunersen for Dravet syndrome in collaboration with Biogen at a recent conference.
Alpha Tau Medical Gains: Alpha Tau Medical's shares surged by 25.26% to $5.30 after announcing the treatment of its first patient in a pilot study for recurrent glioblastoma multiforme using its Alpha DaRT technology.
FDA Designation for Senti Biosciences: Senti Biosciences' stock increased to $1.60 (+3.92%) following the FDA granting RMAT designation to its investigational CAR-NK cell therapy for acute myeloid leukemia and other hematologic malignancies.
COMPASS Pathways Reports ADS GAAP EPS of -$1.44, Falling Short by $1.05
Q3 Financial Performance: COMPASS Pathways reported a Q3 GAAP EPS of -$1.44, missing expectations by $1.05, while cash and cash equivalents increased to $185.9 million as of September 30, 2025.
Operating Cash Forecast: The company anticipates a full year 2025 net cash usage in operating activities between $120 million to $145 million, with sufficient cash to cover expenses and capital needs into 2027.
Compass Pathways Names Dr. Jeffrey Jonas to Its Board of Directors
New Board Appointment: Compass Pathways has appointed Dr. Jeffrey Jonas to its Board of Directors, bringing over 30 years of experience in pharmaceutical research and neuroscience, effective immediately.
Retirement Announcement: Thomas Lönngren will retire from the Board at the end of December after more than six years of service, during which he contributed to the company's transition from early-stage to late-stage clinical development.
COMP360 Program Focus: The company is advancing its investigational COMP360 synthetic psilocybin treatment for treatment-resistant depression, which has received Breakthrough Therapy designation from the FDA.
Commitment to Mental Health Innovation: Dr. Jonas expressed enthusiasm for supporting Compass Pathways in transforming mental health care through innovative treatments, emphasizing the urgent need for effective solutions in the growing mental health crisis.
Trump Administration Blocks FDA Fast-Track for Psychedelic Treatment
- FDA Plan Rejected: The Trump administration officials declined to approve the FDA's plan to fast-track Compass Pathways' (CMPS) psychedelic treatment for severe depression, indicating possible internal disagreements that could affect the speed and direction of future drug approvals.
- Drug Not Approved: Although Compass's psychedelic treatment was on the FDA's list for expedited review, it was vetoed when presented to the Health and Human Services Department and the White House, highlighting inconsistencies in policy execution that may lead to decreased market confidence.
- Market Reaction: Compass Pathways shares fell 1.1% in premarket trading following the news, reflecting investor concerns about the company's future drug development prospects, which could impact its financing and R&D capabilities.
- Clinical Trial Plans Stalled: This veto may delay Compass's clinical trial plans for treatment-resistant depression and PTSD, affecting its market competitiveness and commercialization readiness.
Compass Receives FDA Approval for COMP360 PTSD Clinical Trial
- Clinical Trial Launch: The FDA's acceptance of the IND application for COMP360 enables Compass to initiate a Phase 2b/3 clinical trial for PTSD, which is expected to significantly advance the development of new therapies and meet the urgent market demand for effective treatments.
- Commercialization Readiness: Compass is preparing for the market launch of COMP360 for treatment-resistant depression (TRD) by the end of 2026, aiming to address the current gap in the market with only two FDA-approved medications available for approximately 4 million TRD patients.
- Strategic Collaboration Expansion: Compass has partnered with Radial, a national network of mental health treatment clinics, to enhance the integration of COMP360 into various healthcare settings, thereby increasing its market competitiveness and improving patient access to treatment.
- Increased Financial Flexibility: Compass amended its loan agreement with Hercules Capital to increase the loan size to $150 million, providing greater financial flexibility to support future clinical trials and commercialization efforts, ensuring the company maintains sufficient cash flow through 2027.
Compass Pathways Partners with Radial Health to Advance COMP360 Treatment Models
- Strategic Collaboration Expansion: Compass Pathways has entered its seventh strategic collaboration with Radial Health to optimize scalable delivery models for the COMP360 psilocybin treatment, which could significantly enhance patient treatment options if FDA approved.
- National Network Development: Radial Health operates across five states in the U.S., aiming to build a national network of interventional psychiatry clinics, and through collaboration with Compass, will facilitate the integration of innovative treatment options to improve patient experiences.
- Innovative Treatment Potential: The COMP360 psilocybin treatment is viewed as a potential paradigm shift in mental health treatment, and both parties will explore its application within Radial's delivery model, which could provide more effective treatment options for patients if successful.
- Diverse Collaboration Model: Compass has established partnerships with various mental health organizations, gathering valuable insights on how the COMP360 treatment can be integrated into different healthcare settings, thereby enhancing its market acceptance.
Post-Market Surge: Stoke Therapeutics, Alpha Tau Medical, and Compass Pathways Top Biotech Gainers
Biotech Stock Movements: Biotech stocks experienced significant fluctuations in after-hours trading, with several companies rebounding after losses during regular trading hours, driven by clinical data, FDA designations, and financing news.
Stoke Therapeutics Surge: Stoke Therapeutics saw its stock rise to $33.95 (+11.42%) after presenting positive data on zorevunersen for Dravet syndrome in collaboration with Biogen at a recent conference.
Alpha Tau Medical Gains: Alpha Tau Medical's shares surged by 25.26% to $5.30 after announcing the treatment of its first patient in a pilot study for recurrent glioblastoma multiforme using its Alpha DaRT technology.
FDA Designation for Senti Biosciences: Senti Biosciences' stock increased to $1.60 (+3.92%) following the FDA granting RMAT designation to its investigational CAR-NK cell therapy for acute myeloid leukemia and other hematologic malignancies.
COMPASS Pathways Reports ADS GAAP EPS of -$1.44, Falling Short by $1.05
Q3 Financial Performance: COMPASS Pathways reported a Q3 GAAP EPS of -$1.44, missing expectations by $1.05, while cash and cash equivalents increased to $185.9 million as of September 30, 2025.
Operating Cash Forecast: The company anticipates a full year 2025 net cash usage in operating activities between $120 million to $145 million, with sufficient cash to cover expenses and capital needs into 2027.
Compass Pathways Names Dr. Jeffrey Jonas to Its Board of Directors
New Board Appointment: Compass Pathways has appointed Dr. Jeffrey Jonas to its Board of Directors, bringing over 30 years of experience in pharmaceutical research and neuroscience, effective immediately.
Retirement Announcement: Thomas Lönngren will retire from the Board at the end of December after more than six years of service, during which he contributed to the company's transition from early-stage to late-stage clinical development.
COMP360 Program Focus: The company is advancing its investigational COMP360 synthetic psilocybin treatment for treatment-resistant depression, which has received Breakthrough Therapy designation from the FDA.
Commitment to Mental Health Innovation: Dr. Jonas expressed enthusiasm for supporting Compass Pathways in transforming mental health care through innovative treatments, emphasizing the urgent need for effective solutions in the growing mental health crisis.
